Table 2.
Molecular data and outcome of the 13 patients enrolled in the trial.
| Patient | Gene MMR Mutations | MSI | TMB (muts/Mb) | PD-L1 (% Tumor Cells) | MHC-1 (% Tumor Cells) | Macrophage Density (n/mm2) | CD8+ Density (n/mm2) | Response | PFS (Months) | OS (Months) |
|---|---|---|---|---|---|---|---|---|---|---|
| 1PD * | none | absent | 13.4 | 0 | 40 | 360.20 | 8.10 | SD | 5.29 | 9.00 |
| 2PD | none | absent | 7.7 | 0 | 75 | 605.20 | 20.00 | PD | 1.12 | 1.68 |
| 3PD * | none | absent | 9.78 | 0 | 30 | 971.20 | 45.40 | PD | 0.92 | 1.68 |
| 4PD * | none | absent | 10.26 | 0 | 95 | 680.60 | 11.80 | PD | 2.37 | 3.61 |
| 5PD | none | absent | 13.28 | 0 | 0 | 108.90 | 21.20 | PD | 1.54 | 29.40 ° |
| 9PD | none | absent | 8.45 | 0 | 0 | 140.10 | 38.80 | PD | 0.69 | 1.15 |
| 10PD | none | absent | 13.93 | 3 | 70 | 454.70 | 84.90 | SD | 7.36 | 19.98 |
| 12PD * | none | absent | 6.76 | 0 | 50 | 328.00 | 0.00 | PD | 2.23 | 2.76 |
| 13_1PD | none | absent | 10.84 | 5 | 70 | 393.00 | 90.70 | PD | 1.84 | 18.20 ° |
| 16PD | none | absent | 8.97 | 0 | 0 | 256.79 | 3.75 | SD | 16.76 | 21.36 |
| 17PD | MSH6 | absent | 26.89 | 0 | 90 | 483.10 | 30.60 | PD | 2.14 | 2.79 |
| 18PD | none | absent | 9.33 | 0 | 95 | 665.30 | 52.00 | SD | 8.11 | 23.13 ° |
| 21PD | n.d. | n.d. | n.d. | 0 | n.d. | n.d. | n.d. | PD | 3.09 | 5.59 |
* In these cases, histological and molecular analyses were performed on primary tumors, in all other cases on recurrent tumors (all pts received temozolomide and RT as first treatment); °: censored; n.d.: not done; SD: stable disease; PD: progressive disease. MMR: mismatch repair; MSI: microsatellite instability; TMB: tumor mutational burden; PFS: progression-free survival; OS: overall survival.